Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
COMBINATIONAL THERAPY FOR MELANOMA USING ZEBULARINE AS AN EPIGENETIC INHIBITOR AND TOLL-LIKE RECEPTOR AGONISTS AS IMMUNOTHERAPY
Download
Havva_Homak_Master_Thesis.pdf
HAVVA HOMAK.pdf
Date
2025-8
Author
Homak, Havva
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
607
views
0
downloads
Cite This
Oncotherapy faces significant obstacles due to the complex nature of cancer. Notably, therapy-induced or tumor-mediated immunosuppression and cancer recurrence after remission remain substantial challenges. Emerging modalities such as immunotherapy, which augments the cytotoxic activity of immune cells, and epigenetic therapy, which aims to reprogram the genome of malignant cells toward a non-cancerous state, have been developed to address these concerns. However, monotherapies often show limited efficacy in overcoming all these hurdles. This study therefore aims to investigate the potential benefits of combining immunotherapy and epigenetic therapy for melanoma treatment. To achieve this, we screened nine Food and Drug Administration (FDA) approved epigenetic inhibitors for their immunostimulatory properties to identify candidates suitable for combination with a cancer vaccine comprising nucleic acid-based Toll-like receptor (TLR) agonists and ovalbumin as a model antigen. Our findings indicate that zebularine, a DNA methyltransferase (DNMT) inhibitor, when used alongside CpG oligodeoxynucleotides (ODN), a TLR9 agonist, enhances immune responses in murine splenocytes and increases cytotoxicity against B16 melanoma cells. In addition, this combination therapy reduces tumor growth and induces antigen-specific adaptive immune responses in an in vivo melanoma mouse model. In summary, zebularine augments the immune responses elicited by CpG ODN, and their combined administration represents a promising strategy for reprogramming tumor cells and improving therapeutic outcomes.
Subject Keywords
Immunotherapy
,
Epigenetic therapy
,
CpG ODN
,
Zebularine
,
Melanoma
URI
https://hdl.handle.net/11511/115640
Collections
Graduate School of Natural and Applied Sciences, Thesis
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
H. Homak, “COMBINATIONAL THERAPY FOR MELANOMA USING ZEBULARINE AS AN EPIGENETIC INHIBITOR AND TOLL-LIKE RECEPTOR AGONISTS AS IMMUNOTHERAPY,” M.S. - Master of Science, Middle East Technical University, 2025.